Filed: 5/9/2023ACC: 0001910264-23-000002
📋 What this filing means
SR ONE CAPITAL MANAGEMENT, LP filed this quarterly 13F‑HR report disclosing 5 equity positions with a total reported market value of $240.36M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
5
Positions
$240.36M
Total AUM (reported)
24.19M
Total Shares
Allocation by class
COMMON STOCK$169.46M70.5%
COM$70.90M29.5%
Portfolio Concentration
Top 3$233.24M97.0%
4–10$7.12M3.0%
Top 3 weight
97.0%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 24.19M
Sole
Full voting authority
24.19M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole5
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings5
Rows:
ARCELLX INC.
SOLEShares5.50M
TypeSH
Market value$169.46M
70.50%
Sole
5.50M
Shared
0.00
None
0.00
DESIGN THERAPEUTICS INC
SOLEShares6.53M
TypeSH
Market value$37.66M
15.67%
Sole
6.53M
Shared
0.00
None
0.00
ARS PHARMACEUTICALS
SOLEShares4.01M
TypeSH
Market value$26.12M
10.87%
Sole
4.01M
Shared
0.00
None
0.00
NKARTA INC.
SOLEShares1.33M
TypeSH
Market value$4.73M
1.97%
Sole
1.33M
Shared
0.00
None
0.00
EFFECTOR THERAPEUTICS INC
SOLEShares6.82M
TypeSH
Market value$2.39M
0.99%
Sole
6.82M
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
ARCELLX INC.SOLE | COMMON STOCK | 5.50M | SH | $169.46M 70.50% | 5.50M | 0.00 | 0.00 |
DESIGN THERAPEUTICS INCSOLE | COM | 6.53M | SH | $37.66M 15.67% | 6.53M | 0.00 | 0.00 |
ARS PHARMACEUTICALSSOLE | COM | 4.01M | SH | $26.12M 10.87% | 4.01M | 0.00 | 0.00 |
NKARTA INC.SOLE | COM | 1.33M | SH | $4.73M 1.97% | 1.33M | 0.00 | 0.00 |
EFFECTOR THERAPEUTICS INCSOLE | COM | 6.82M | SH | $2.39M 0.99% | 6.82M | 0.00 | 0.00 |